Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2024-03-19 00:00:00 ET · period of report 2024-03-15 · accession 0001140361-24-014164 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-03-19 | 2024-03-15 | GYRE | USMAN NASSIM | Dir | S - Sale+OE | $17.26 | -20.0K | 1,636 | -92% | -$345.2K |
| DT | 2024-03-19 | 2024-03-15 | GYRE | USMAN NASSIM | Dir | M - OptEx | $6.93 | +20.0K | 21.6K | +1,222% | +$138.6K |
| DT | 2024-03-19 | 2024-03-15 | GYRE | USMAN NASSIM | Dir | M - OptEx | $0.00 | -20.0K | 321.7K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | S | D | 20,000 | $17.26 | 1,636 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $16.07 to $18.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-03-15 | M | A | 20,000 | $6.93 | 21,636 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-03-15 | M | D | 20,000 | $0.00 | 321,652 | D | $6.93 · — to 2033-10-31 | 20,000 Common Stock | (F3) This option is vested in full. |